USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/13145
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChilari, Mihaela
dc.contributor.authorChianu, Marin
dc.date.accessioned2020-11-22T15:21:13Z
dc.date.available2020-11-22T15:21:13Z
dc.date.issued2020-10
dc.identifier.urihttps://stiinta.usmf.md/ro/manifestari-stiintifice/zilele-universitatii
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/13145
dc.descriptionChair Psychiatry narcology and medical psychology, SMUPh ”Nicolae Testemitanu”, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltareen_US
dc.description.abstractIntroduction Neuroleptic malignant syndrome (NMS) as an adverse reaction to the use of atypical neuroleptics (AN) is present in 0.02 - 3 % of patients, being determined by age, sex, diagnosis and the group of atypical neuroleptics that were administered. Purpose Analysis and systematization of the adverse reactions (neuroleptic malignant syndrome) produced by atypical neuroleptics. Material and methods The articles from the PubMed and MEDLINE database were selected and analyzed according to the keywords “neuroleptic malignant syndrome”, “atypical antipsychotic drugs”, “treatment of schizophrenia”. Results The pathophysiology of this adverse reaction is not fully elucidated, a hypothesis is the rapid blockade of D2 receptors in the CNS. NMS includes such symptoms as: instability, extrapyramidal disorders, hyperpyrexia, and altered mental state. When using AN as clozapine, risperidone, olanzapine and quentiapine SNM occurred on average on the 14th day. Thus, on the background of the treatment with clozapine SNM was manifested in 30%, in the administration of risperidone in 38%, in the administration of olanzapine in 27%, and quentiapine in 5% of cases. Conclusions Thus, we can say that in terms of treatment with AN, the SNM rate is lower than with the use of typical neuroleptics or it may simply be a reflection of doctors' awareness and the follow-up of early treatment with more harmless and contemporary drugs.en_US
dc.language.isoenen_US
dc.publisherUniversitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu" din Republica Moldovaen_US
dc.subjectneuroleptic malignant syndromeen_US
dc.subjectatypical neurolepticsen_US
dc.titleMalignant neuroleptic syndrome in the use of atypical neuroleptics in the treatment of schizophreniaen_US
dc.typeOtheren_US
Appears in Collections:Culegere de postere

Files in This Item:
File Description SizeFormat 
42_160_235.pdf179.81 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback